About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for … About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals, Inc is primarely in the business of pharmaceutical preparations. Zynerba presents a poster in ZYN002. Zynerba Pharmaceuticals is currently evaluating two patent protected product candidates, ZYN002 and ZYN001, in four neuropsychiatric indications. By Dec 30, 2020, it held 4.4% of the shares, which is about 1.81 Million shares worth $5.99 Million. Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021 . For financial reporting, their fiscal year ends on December 31st. About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for … Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) traded at $5.64 at close of the session on Friday, June 11, made an upward move of 4.06% on its previous day’s price. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) has a beta value of 2.49 and has seen 1.13 million shares traded in the last trading session. Trova l’ultima quotazione dei titoli di Zynerba Pharmaceuticals, Inc. (ZYNE), cronologia, notizie e altre informazioni essenziali per scambiare titoli e investire al meglio. Zynerba Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $5, moving -0.79% from the previous trading session. The company’s stock price has collected 9.30% of gains in the last five trading sessions. Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside. The Investor Relations website contains information about Zynerba Pharmaceuticals Inc's business for stockholders, potential investors, and financial analysts. About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for … DEVON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2021, and provided an overview of recent operational highlights and a pipeline update. Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. Press Release reported on 06/11/21 that Zynerba Pharmaceuticals Presents At the time, we recommended the shares were … Advancing science as a biotechnology company rarely goes exactly as planned, and Zynerba Pharmaceuticals (ZYNE) is no exception. What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The Investor Relations website contains information about Zynerba Pharmaceuticals Inc's business for stockholders, potential investors, and financial analysts. About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for … Headline. In 2017, the company completed three Phase 2 clinical trials for ZYN002 and two of those studies have open-label extensions that are ongoing. The Investor Relations website contains information about Zynerba Pharmaceuticals Inc's business for stockholders, potential investors, and financial analysts. trademarks are property of their Zynerba Pharmaceuticals (NASDAQ: ZYNE) A Rare/Near-Rare Neuropsychiatric Company The company report on May 17, 2021 that Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference.. Get the hottest stocks to trade every day before the market opens … 05.26. Zynerba Pharmaceuticals, Inc. (ZYNE) estimates and forecasts. Zynerba Pharmaceuticals, Inc. earnings are expected to decrease by -26.9% in 2021, but the outlook is negative 0% per year for the next five years. ZYNE has a Sell rating from none of the analyst(s) out of 7 analysts who have looked at this stock. Zynerba Pharmaceuticals showcases Zygel study poster at annual SLEEP meeting. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 7.6%. We have been trying to reach you in connection with the Annual Meeting of Stockholders of Zynerba Pharmaceuticals, Inc. (the “Annual Meeting”), which was originally scheduled to be held at 10:00 a.m. EDT on June 9, 2021 but has been adjourned … The 2021 estimates are for Zynerba Pharmaceuticals, Inc. earnings to decrease by -26.9%, but the outlook for the next 5-year period is at 0% per year. Zynerba Pharmaceuticals (NASDAQ:ZYNE) is dedicated to improving the lives of people with severe health conditions where there is a high unmet medical need by developing and commercializing pharmaceutically-produced transdermal cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. Get the hottest stocks to trade every day before the market opens 100% free. Get the latest Zynerba Pharmaceuticals Inc (ZYNE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The company report on April 15, 2021 that Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2 Both posters will be made available on the Zynerba corporate website at the time of their presentations at http://zynerba.com/publications/. During … A look at the daily … Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) gained after presenting a poster at the 2021 SLEEP 35th Annual Meeting of the Associated Sleep Societies. The company, currently valued at $215.30M, closed the last trade at $5.43 per share which meant it lost -$0.23 on the day or -4.06% during that session. Read More. Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) investors should pay attention to an increase in activity from the world's largest hedge funds of … Looking at the stock we see that its p Zynerba Pharmaceuticals, Inc. stock is held by 75 institutions, with ETF Managers Group, LLC being the largest institutional investor. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest Down 35.5% in May. Zynerba Pharmaceuticals, Inc. has a market cap of $193.89 Million and is expected to release its quarterly earnings report on November 09, 2020. That translates to a mean rating of 2. We are going to peek back in on small biopharma Zynerba Pharmaceuticals since we posted an article on it to begin 2020. proactiveinvestors.com - June 11 at 7:46 PM. Devon, PA, September 14, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided an update on its Fragile X syndrome (FXS) and developmental and epileptic encephalopathies (DEE) programs. Zynerba Pharmaceuticals, Inc. (ZYNE) projections and forecasts. About Zynerba Pharmaceuticals Inc Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. americanbankingnews.com - June 14 at 6:18 AM. A copy of the poster is available on the Zynerba corporate website … Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to … Zynerba Pharmaceuticals Inc. (ZYNE) EPS growth this year is -26.90%: Get Prepared for Trading Lift Off Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) open the trading on June 15, 2021, with a bit cautious approach as it glided -4.06% to $5.43. Click here now. DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. 2 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 5 recommend a Buy rating for it. ZYNE | Complete Zynerba Pharmaceuticals Inc. stock news by MarketWatch. Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome GlobeNewswire Inc. - 5/5/2021 4:05:00 PM: Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting GlobeNewswire Inc. - 4/29/2021 2:00:00 PM View real-time stock prices and stock quotes for a full financial overview. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.6%. Press Release reported on 04/06/21 that Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 4.84% from its latest closing price compared to the recent 1-year high of $9.00. Read More. The company’s stock price has collected -0.46% of loss in the last five trading sessions. Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies. Zynerba Pharmaceuticals, Inc. (ZYNE) received a consensus recommendation of Overweight from analysts. The poster was titled, “ Impact of ZYN002 Cannabidiol Transdermal Gel on Sleep in Children and Adolescents with Developmental and Epileptic Encephalopathies and Comorbid Autism Spectrum … DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster recently at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC. Zynerba (ZYNE) Alert: Shareholder Class Action... Zynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. Click here now. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) price is hovering lower on Wednesday, May 12, sinking -0.24% below its previous close. Zynerba Pharmaceuticals Inc. [NASDAQ: ZYNE] jumped around 0.58 points on Wednesday, while shares priced at $4.41 at the close of the session, up 15.14%. Zynerba Pharmaceuticals, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 4.06% from its latest closing price compared to the recent 1-year high of $9.00. Get the hottest stocks to trade every day before the market opens 100% free. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ZYNE stock to lose ahead of the earnings release. About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals Inc. [NASDAQ: ZYNE] price surged by 5.77 percent to reach at $0.27. Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference.
Plus Pharma Daily Vitamin Formula + Minerals, Michigan Governor Salary And Benefits, Woocommerce Image Editor, Google Form Date Picker Mobile, Formula Feeding Chart, Most Inbred Place In Scotland, Wasted Tv Show Rotten Tomatoes, Uniworld Covid Update, Arcgis Experience Builder Charts,
JUN